Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib

Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib

Background: Acute respiratory distress syndrome (ARDS) in corona virus disease 19 (COVID-19) is triggered by hyperinflammation, thus providing a rationale for immunosuppressive treatments. The Janus kinase inhibitor Ruxolitinib (Ruxo) has shown efficacy in severe and critical COVID-19. In this study...

Fuld beskrivelse

Gespeichert in:
Bibliografiske detaljer
Autoren: Völkel, Sara, Tarawneh, Thomas S., Sacher, Laura, Bhagwat, Aditya M., Karim, Ihab, Mack, Hildegard I. D., Wiesmann, Thomas, Beutel, Gjörn, Hoyer, Joachim, Keller, Christian, Renz, Harald, Burchert, Andreas, Neubauer, Andreas, Graumann, Johannes, Skevaki, Chrysanthi, Mack, Elisabeth K. M.
Format: Artikel
Sprog:engelsk
Udgivet: Philipps-Universität Marburg 2023
Fag:
SARS-CoV-2
proteomics
COVID-19
Medizin
acute respiratory distress syndrome
Ruxolitinib
Medical sciences Medicine
Online adgang:PDF-Volltext
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
Publikationen im Open Access gefördert durch die UB

Lignende værker